| Systematic comparison of constitutive promoters and the doxycycline-inducible promoter JY Qin, L Zhang, KL Clift, I Hulur, AP Xiang, BZ Ren, BT Lahn PloS one 5 (5), e10611, 2010 | 732 | 2010 |
| Genomic hallmarks and structural variation in metastatic prostate cancer DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ... Cell 174 (3), 758-769. e9, 2018 | 683 | 2018 |
| Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study R Aggarwal, J Huang, JJ Alumkal, L Zhang, FY Feng, GV Thomas, ... Journal of Clinical Oncology 36 (24), 2492-2503, 2018 | 660 | 2018 |
| Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang, Y Cheng, J He, Y Shi, ... JAMA oncology 4 (11), 1569-1575, 2018 | 540 | 2018 |
| Nestin is required for the proper self-renewal of neural stem cells D Park, AP Xiang, FF Mao, L Zhang, CG Di, XM Liu, Y Shao, BF Ma, ... Stem cells 28 (12), 2162-2171, 2010 | 443 | 2010 |
| The DNA methylation landscape of advanced prostate cancer SG Zhao, WS Chen, H Li, A Foye, M Zhang, M Sjöström, R Aggarwal, ... Nature genetics 52 (8), 778-789, 2020 | 258 | 2020 |
| Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire DY Oh, J Cham, L Zhang, G Fong, SS Kwek, M Klinger, M Faham, L Fong Cancer research 77 (6), 1322-1330, 2017 | 230 | 2017 |
| Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 … TA Hope, M Eiber, WR Armstrong, R Juarez, V Murthy, C Lawhn-Heath, ... JAMA oncology 7 (11), 1635-1642, 2021 | 228 | 2021 |
| Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer RM Hicks, JP Simko, AC Westphalen, HG Nguyen, KL Greene, L Zhang, ... Radiology 289 (3), 730-737, 2018 | 148 | 2018 |
| Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer WS Chen, R Aggarwal, L Zhang, SG Zhao, GV Thomas, TM Beer, ... European urology 76 (5), 562-571, 2019 | 139 | 2019 |
| Clonal deletion of tumor-specific T cells by interferon-γ confers therapeutic resistance to combination immune checkpoint blockade CCS Pai, JT Huang, X Lu, DM Simons, C Park, A Chang, W Tamaki, E Liu, ... Immunity 50 (2), 477-492. e8, 2019 | 118 | 2019 |
| Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol RU Newton, SA Kenfield, NH Hart, JM Chan, KS Courneya, J Catto, ... BMJ open 8 (5), e022899, 2018 | 117 | 2018 |
| Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis J Madzo, H Liu, A Rodriguez, A Vasanthakumar, S Sundaravel, ... Cell reports 6 (1), 231-244, 2014 | 117 | 2014 |
| At what cost to clinical trial enrollment? A retrospective study of patient travel burden in cancer clinical trials HT Borno, L Zhang, A Siegel, E Chang, CJ Ryan The oncologist 23 (10), 1242-1249, 2018 | 97 | 2018 |
| Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer MA Reimers, SM Yip, L Zhang, M Cieslik, M Dhawan, B Montgomery, ... European urology 77 (3), 333-341, 2020 | 93 | 2020 |
| Protecting against wayward human induced pluripotent stem cells with a suicide gene F Cheng, Q Ke, F Chen, B Cai, Y Gao, C Ye, D Wang, L Zhang, BT Lahn, ... Biomaterials 33 (11), 3195-3204, 2012 | 88 | 2012 |
| The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot? ML Cheng, L Zhang, M Borok, E Chokunonga, C Dzamamala, A Korir, ... Cancer epidemiology 39 (2), 143-149, 2015 | 84 | 2015 |
| 111In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden TA Hope, J Calais, L Zhang, W Dieckmann, C Millo Journal of Nuclear Medicine 60 (9), 1266-1269, 2019 | 81 | 2019 |
| Bone metastases and skeletal-related events from neuroendocrine tumors K Van Loon, L Zhang, J Keiser, C Carrasco, K Glass, MT Ramirez, ... Endocrine Connections 4 (1), 9-17, 2015 | 81 | 2015 |
| Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or … EJ Small, J Huang, J Youngren, A Sokolov, RR Aggarwal, G Thomas, ... Journal of Clinical Oncology 33 (15_suppl), 5003-5003, 2015 | 80 | 2015 |
Lawrence FongProfessor of Medicine, University of California, San Francisco在 ucsf.edu 的电子邮件经过验证
